AUROPHARMA vs LYKALABS: Stock Comparison
AUROBINDO PHARMA is the larger company by market capitalisation. AUROBINDO PHARMA shows a higher ROE, faster revenue growth and lower leverage, while LYKALABS shows a lower P/E. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
AUROPHARMA leads 9; LYKALABS leads 1 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | AUROPHARMA | LYKALABS |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | AUROPHARMA | LYKALABS |
|---|---|---|
| Live Price | ₹1,610.9 | ₹74.83 |
| Day Change | 2.03% | 1.19% |
| Volume | 11.16 L | 88,556 |
| 52-Week High | ₹1,740 | ₹98.9 |
| 52-Week Low | ₹1,080.1 | ₹44.1 |
| Distance from 52W High | -7.42% | -24.34% |
Valuation
| Metric | AUROPHARMA | LYKALABS |
|---|---|---|
| Market Cap | ₹93,556 Cr | ₹308 Cr |
| P/E Ratio | 25.37x | 0x |
| P/B Ratio | 2.49x | 2.67x |
| EPS | ₹64 | ₹0.57 |
| Book Value | ₹652.39 | ₹25.12 |
| Dividend Yield | 0% | 0% |
Growth
| Metric | AUROPHARMA | LYKALABS |
|---|---|---|
| Revenue Growth (TTM YoY) | 5.6% | 0% |
| EPS Growth (TTM YoY) | 1.9% | 0% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | AUROPHARMA | LYKALABS |
|---|---|---|
| ROE | 10.63% | -37.11% |
| ROCE | 9.64% | -22.29% |
| Net Margin | 10.62% | -7.81% |
| Operating Margin | 30.23% | -24.74% |
| Debt to Equity | 0.18x | 0.56x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | AUROPHARMA | LYKALABS |
|---|---|---|
| Promoter Holding | 48.8%▼ 0.01 pp | 58.45% |
| FII Holding | 17.41%▲ 1.03 pp | 0.15%▼ 0.02 pp |
| DII Holding | 24.42%▼ 0.68 pp | 0.66% |
| Public Holding | 6.29%▼ 0.35 pp | 40.73%▲ 0.01 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: AUROBINDO PHARMA and LYKALABS.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.